Quantcast

Latest Glioma Stories

2014-05-31 16:20:13

Single agent NKTR-102 exceeds primary endpoint with fifty-five percent of patients achieving six-week progression-free survival and fifteen percent of patients achieving partial response SAN FRANCISCO, May 31, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced today new data from an investigator-sponsored Phase 2 study of NKTR-102 (etirinotecan pegol) in patients with Avastin-refractory high-grade glioma conducted at Stanford Cancer Institute under the direction of...

2014-05-31 08:20:41

VANCOUVER, British Columbia and MENLO PARK, Calif., May 31, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") announced the presentation of interim clinical data from the company's ongoing clinical trial with VAL-083 in refractory glioblastoma multiforme (GBM) during the Central Nervous System Tumor Session at the 50(th) Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held at the McCormick Place Convention Center in Chicago. In...

2014-05-30 08:24:56

- Results from Phase I study of investigational oncology compound ABT-414 in patients with recurrent or unresectable glioblastoma multiforme, an aggressive type of brain cancer NORTH CHICAGO, Ill., May 30, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) released preliminary results from an ongoing Phase I study with ABT-414, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody drug conjugate, in combination with temozolomide, which showed four objective responses, including one...

2014-05-22 08:29:48

In Addition, Toca 511 Clinical Data to be Presented at American Society of Clinical Oncology Annual Meeting SAN DIEGO, May 22, 2014 /PRNewswire/ -- Tocagen Inc. today announced multiple scientific contributions at the American Society of Gene and Cell Therapy (ASGCT) 17(th) Annual Meeting, held May 21 to 24, 2014 at the Marriott Wardman Park in Washington, DC. At the ASGCT Annual Meeting, data from clinical and preclinical studies of Toca 511 will be presented in two podium presentations:...

2014-05-20 08:31:42

CALGARY, May 20, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that an abstract detailing early results from translational study looking at the intravenous administration of REOLYSIN(®) to patients with primary or metastatic brain tumors is now available on the ASCO Annual Meeting abstract website at http://abstracts.asco.org. The conference is being held from May 30(th) to June 3(rd), 2014 in Chicago, Illinois. "Treatment...

2014-05-16 08:26:16

30mg/m2 dose cohort had been completed; enrollment of 40mg/m2 cohort has been initiated VANCOUVER, British Columbia and MENLO PARK, Calif., May 16, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") is pleased to provide an update on the company's ongoing Phase I/II clinical trial for VAL-083 in recurrent glioblastoma multiforme (GBM). DelMar has completed enrollment of VAL-083 dose Cohort 6 and advanced to Cohort 7. DelMar most recently presented...

2014-05-06 23:03:44

Wildlife Correspondent to Help Raise Awareness of 700,000 Living with a Brain Tumor Chicago, IL (PRWEB) May 06, 2014 Inspired by his daughter’s courageous battle against brain tumors, Wildlife Correspondent Jack Hanna has teamed up with the American Brain Tumor Association to raise awareness and promote greater understanding of the disease in observation of Brain Tumor Awareness Month this May. At the age of 2, Hanna’s youngest daughter, Julie, was diagnosed with leukemia and went...

2014-04-17 08:28:12

VISIUS intraoperative MRI significantly enhances amount of complete resection in brain tumors and leads to better patient outcomes MINNEAPOLIS, April 17, 2014 /PRNewswire/ - IMRIS Inc. (NASDAQ: IMRS; TSX: IM) ("IMRIS" or the "Company") today announced that a study published this month in the journal Neurosurgery by the neurosurgical team at Cleveland Clinic adds to growing clinical evidence which validates use of high-field intraoperative MRI (iMRI) as an effective tool for...

2014-04-11 08:24:10

CALGARY, April 11, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that Dr. Alan Melcher, Professor of Clinical Oncology and Biotherapy at the University of Leeds, presented at the 8(th) Annual International Conference on Oncolytic Virus Therapeutics held in Oxford, UK. Dr. Melcher's presentation, titled "Clinical Virotherapy and Immune Modulation; Bench to Bedside and Back Again," covered early clinical research showing that...

2014-04-10 08:29:39

Results Continue to Show Safety and Promising Survival; Program to Advance into a Randomized, Controlled Trial SAN DIEGO, April 10, 2014 /PRNewswire/ -- Tocagen Inc. today announced that updated interim clinical data from two ongoing investigational studies of Toca 511 in combination with Toca FC in 68 patients with recurrent high grade glioma were presented at the American Association of Neurological Surgeons (AANS) Annual Meeting in San Francisco. High grade gliomas include...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.